In 2019, Loupakis et al. developed an intriguing prognostic score for BRAF-mutated mCRC, including eight covariates: Eastern Cooperative Oncology Group (ECOG) Performance Status, CA19.9, Lactate Dehydrogenase (LDH), NLR (Neutrophil-to-Lymphocyte Ratio), tumor grading, liver metastases, lung metastases, and nodal metastases [30]. This evidence concerns the gene BRAF and neoplasm.